Checkpoint price target lowered to $4.80 from $9 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Checkpoint Therapeutics (CKPT) to $4.80 from $9 and keeps a Buy rating on the shares. The firm cites the pending takeover by Sun Pharma plus the contingent value right of up to $71M for the new price target The structure provides stockholders with immediate value while offering potential upside upon achieving regulatory milestones, the analyst tells investors in a research note.